Bass Explains The Absurdity Of Horizon Pharma’s Vimovo Patent

It hasn’t been a full day since we reported Kyle Bass’s last pharma patent challenge against Pozen, and his patent busting hedge fund Coalition for Affordable Drugs has already filed another, this time against Horizon Pharma’s patent on Vimovo. “Vimovo is a drug that merely combines a generic pain reliever with a generic acid inhibitor—but it costs 66 times more than its component parts based solely on the fact that a single patent examiner issued (in error) the ‘907 patent,” Bass writes on Harvest. Since Vimovo makes up more than half of Horizon’s 2014 sales and an even larger chunk…